Medical News

RSS

Researchers receive Special Challenge Award to investigate role of high protein levels in prostate tumors

Cleveland Clinic, along with the National Cancer Institute, the University of Chicago and Thomas Jefferson University, are the recipients of a $600,000 Special Challenge Award from the Prostate Cancer Foundation (PCF) to investigate the role of abnormally high protein levels in prostate tumors.

18 Dec 2013

Federal officials begin sending states applications from residents eligible for Medicaid

The administration is delivering the data to states so that they can enroll new applicants. Meanwhile, in Virginia, the legislative panel holds its last meeting of the year without a recommendation about Medicaid expansion and Colorado reports its latest enrollment figures.

18 Dec 2013

Alexandria-based Prevent Cancer Foundation gets $5,000 grant from Cardinal Bank Community

Cardinal Bank announced today that the Cardinal Bank Community Fund has awarded $5,000 to the Prevent Cancer Foundation. The mission of the Alexandria-based organization is to save lives through cancer prevention and early detection, and it has provided more than $130 million to support cancer prevention, early detection research, education, advocacy, and community outreach nationwide.

18 Dec 2013

Study finds relationship between quality of children's diets and elders in representative communities

Understanding how dietary habits are connected through the generations could have valuable benefits for community health, a new study shows.

18 Dec 2013

Aerobic glycolysis is a cause of malignancy, show Berkeley Lab researchers

Metabolism was lost in the shadows of cancer research for decades but has recently been reclaiming some of the spotlight. Now, Mina Bissell, Distinguished Scientist with Berkeley Lab's Life Sciences Division and a leading authority on breast cancer, has shown that aerobic glycolysis - glucose metabolism in the presence of oxygen - is not the consequence of the cancerous activity of malignant cells but is itself a cancerous event.

18 Dec 2013

Simple HPV home tests could identify women at risk for cervical cancer

HPV self-testing is as effective as tests done by doctors, according to a Lund University study. Simple HPV home tests could therefore complement existing screening programmes, and identify more women at risk for cervical cancer.

18 Dec 2013

UCD Conway Institute researchers identify potential biomarker of idiopathic pulmonary ﬁbrosis

Researchers in UCD Conway Institute have identified a potential biomarker of rapidly progressive pulmonary fibrosis and pinpointed a defective molecular function as a potential therapeutic target.

18 Dec 2013

St. Louis College of Pharmacy's Amy Tiemeier suggests four easy resolutions for a healthier 2014

With the new year quickly approaching, many are beginning to think about resolutions. Amy Tiemeier, Pharm.D., BCPS, associate professor of pharmacy practice at St. Louis College of Pharmacy suggests four easy resolutions for a healthier 2014.

18 Dec 2013

Merck signs license agreement with CNIO for cancer drug development

Merck Serono, the biopharmaceutical division of Merck, today announced that a license agreement has been signed with the Spanish National Cancer Research Centre in Madrid in the area of cancer drug development. The global agreement will build upon CNIO research discoveries to encourage the development and commercialization of new compounds in the field of oncology.

18 Dec 2013

Elekta to launch MOSAIQ oncology information system throughout McLaren's cancer network

The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care to launch MOSAIQ oncology information system throughout McLaren's cancer network.

From Elekta 18 Dec 2013

Mylan obtains exclusive rights from Pfizer to develop, commercialize novel LAMA compound

Mylan Inc. today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist compound for various indications.

18 Dec 2013

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014.

18 Dec 2013

Oticon Medical obtains FDA clearance to market Ponto Plus bone anchored sound processors

Oticon Medical has obtained 510(k) clearance from the U.S. Food and Drug Administration to market Ponto Plus, the company's newest family of bone anchored sound processors. New Ponto Plus is available in regular and power versions and is designed for use with Oticon Medical's proprietary OptiFit/OptiGrip implant design concepts that have also been cleared by the FDA for use in tissue-preserving surgery.

18 Dec 2013

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Merck, known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company's investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline's orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma.

18 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.

18 Dec 2013

Medical News

Researchers receive Special Challenge Award to investigate role of high protein levels in prostate tumors

Federal officials begin sending states applications from residents eligible for Medicaid

Alexandria-based Prevent Cancer Foundation gets $5,000 grant from Cardinal Bank Community

Study finds relationship between quality of children's diets and elders in representative communities

Aerobic glycolysis is a cause of malignancy, show Berkeley Lab researchers

Simple HPV home tests could identify women at risk for cervical cancer

UCD Conway Institute researchers identify potential biomarker of idiopathic pulmonary ﬁbrosis

St. Louis College of Pharmacy's Amy Tiemeier suggests four easy resolutions for a healthier 2014

Merck signs license agreement with CNIO for cancer drug development

Elekta to launch MOSAIQ oncology information system throughout McLaren's cancer network

Mylan obtains exclusive rights from Pfizer to develop, commercialize novel LAMA compound

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

Oticon Medical obtains FDA clearance to market Ponto Plus bone anchored sound processors

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

First Edition: December 18, 2013

Primary cilia play key role in stem cell differentiation

Researchers develop potential treatment for atherosclerosis

Chronic pain amongst different ethnic groups: an interview with Professor Martin Underwood, Warwick Medical School

Directed enzyme evolution and the Nobel Prize: Making enzymes evolve in the lab

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Latest News